Nov 14,2023 TOP STORY

Swing Therapeutics Announces Positive Results from Pivotal Phase 3 Trial of Stanza, a Digital Therapy for Fibromyalgia Symptoms

Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, announced the successful completion of and positive results from its pivotal Phase 3 PROSPER-FM trial on Stanza, a self-guided smartphone-based behavioral therapy for the treatment of fibromyalgia symptoms in adult patients. Swing received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for Stanza in May 2023, making it the first prescription digital therapeutic indicated for treating fibromyalgia symptoms. In this 12-week trial, 275 participants were randomized to receive either Stanza treatment or a digital symptom tracker control. The primary outcome measurement was the response rate on the Patient Global Impression of Change (PGIC) Scale. The key secondary endpoint measured fibromyalgia severity using the Revised Fibromyalgia Impact Questionnaire (FIQ-R). Analysis of the intention-to-treat population demonstrated significant clinical benefits of Stanza. At week 12, 70.6% of participants in the Stanza arm reported an improvement on PGIC. Stanza exhibited statistically greater improvement compared to the control on the FIQ-R total score.

CLINICAL STUDY

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Nov 13,2023

Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK

Remote digital health interventions to enhance physical activity provide a potential solution to improve the sedentary behaviour, physical inactivity, and poor health-related quality of life that are typical of chronic conditions, particularly for people with chronic kidney disease. However, there is a need for high-quality evidence to support implementation in clinical practice, according to the researchers. The Kidney BEAM trial evaluated the clinical effect of a 12-week physical activity digital health intervention on health-related quality of life. In a single-blind, randomised controlled trial conducted at 11 centres in the UK, enrolling 340 adult participants with chronic kidney disease were recruited and randomly assigned to the Kidney BEAM physical activity digital health intervention or a waiting list control group. The online platform is hosted by specialist kidney professionals - from renal physiotherapists to renal counsellors - from a number of different NHS trusts and backgrounds, as well as people living with kidney disease. Kidney Beam is aimed at anyone over 16, with any ability, any kidney condition, and at any stage of kidney disease. The primary outcome was the difference in the Kidney Disease Quality of Life Short Form version 1.3 Mental Component Summary (KDQoL-SF1.3 MCS) between baseline and 12 weeks. At 12 weeks, there was a significant improvement in KDQoL-SF.13 MCS score in the Kidney BEAM group compared with the waiting list control group.

CLINICAL STUDY

#virtual care

View Analyst & Ambassador Comments
Go to original news
Nov 13,2023

Dario Publishes New Research Demonstrating That Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose

DarioHealth announced new research presented at the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes. The new study examined the blood glucose and walking data of 989 Dario users to understand the impact of integrating clinical and behavioral data in a single digital app-based experience. The results demonstrated significantly reduced blood glucose levels in the first four months of using Dario and increased step levels in the same timeframe maintained for 12 months. In addition, the results demonstrated clinically significant reductions in blood glucose levels in users who tracked at least 400 steps per day. The research was conducted in partnership with the Integrative Pain Laboratory, School of Public Health at the University of Haifa.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023

Fitterfly showcases outcomes for children with type 2 Diabetes

In a groundbreaking move towards pediatric healthcare, Fitterfly announced its success with managing diabetes in children with Type 2 diabetes with personalised lifestyle interventions using its platform. While the key lies in achieving weight loss of around 10% with nutrition, fitness, stress and sleep management interventions, it is challenging to get children to stick to good habits. A total of 26 children enrolled into the Fitterfly Diabetes program in the last 2 years and of them 11 had type 2 diabetes while 15 had type 1 diabetes. Out of 11 children with type 2 diabetes, 7 finished the program and all of them have reduced HbA1c. The reduction was an average of 1.9 points which is equivalent or better than a combination diabetes oral therapy. In the same time frame, another 25 kids who enrolled in the Fitterfly weight loss program lost 4.1kg in 3 months signifying effectiveness of digitally led programs.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 13,2023

Dario Publishes New Research Demonstrating That Dario Users That Increased Physical Activity Can Maintain Reduced Blood Glucose

DarioHealth announced new research presented at the Diabetes Technology Society 2023 Meeting on November 7, 2023. The new research demonstrated the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes. The new study examined the blood glucose and walking data of 989 Dario users to understand the impact of integrating clinical and behavioral data in a single digital app-based experience. The results demonstrated significantly reduced blood glucose levels in the first four months of using Dario and increased step levels in the same timeframe maintained for 12 months. In addition, the results demonstrated clinically significant reductions in blood glucose levels in users who tracked at least 400 steps per day. The research was conducted in partnership with the Integrative Pain Laboratory, School of Public Health at the University of Haifa.

CLINICAL STUDY

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023

Fitterfly showcases outcomes for children with type 2 Diabetes

In a groundbreaking move towards pediatric healthcare, Fitterfly announced its success with managing diabetes in children with Type 2 diabetes with personalised lifestyle interventions using its platform. While the key lies in achieving weight loss of around 10% with nutrition, fitness, stress and sleep management interventions, it is challenging to get children to stick to good habits. A total of 26 children enrolled into the Fitterfly Diabetes program in the last 2 years and of them 11 had type 2 diabetes while 15 had type 1 diabetes. Out of 11 children with type 2 diabetes, 7 finished the program and all of them have reduced HbA1c. The reduction was an average of 1.9 points which is equivalent or better than a combination diabetes oral therapy. In the same time frame, another 25 kids who enrolled in the Fitterfly weight loss program lost 4.1kg in 3 months signifying effectiveness of digitally led programs.

CLINICAL STUDY

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 26,2023

Real-world data analysis shows significant improvement in glycaemic management when using a blood glucose monitor connected to the mySugr® app in UK users with type 2 diabetes

Roche announced that real world data shows a significant improvement in glycaemic management when using a blood glucose monitor connected to the mySugr mobile health app in UK users with type 2 diabetes. Previous studies had shown an improvement in people with type 1 diabetes with the use of blood glucose monitors connected with mobile health apps. The aim of this study, currently being presented at the Diabetes UK Professional Conference 2023, was to explore the impact of a blood glucose monitor connected to the mySugr app in UK users with type 2 diabetes, as this population often shows reduced glycaemic outcomes and increased diabetes-related complications. The retrospective analysis looked at 1,229 people from the UK, with both type 1 and type 2 diabetes, who used an Accu-Chek meter connected with the mySugr app. After 4 months of using the mySugr app with a connected blood glucose meter, a statistically significant reduction of 0.44% was observed in the estimated HbA1c in users with type 2 diabetes. A reduction was observed in estimated HbA1c after only one month of use. 

CLINICAL STUDY

#bgm

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 06,2023

Major study validates Owkin’s best in class AI diagnostic for colorectal cancer biomarker aimed at optimizing patient access to immunotherapy

In a peer-reviewed study published today, a team of scientists from French-American techbio Owkin and pathology labs in France present a blind validation of MSIntuit™ CRC, a first-in-class AI-driven digital pathology diagnostic developed by Owkin, as a pre-screening tool aimed at optimizing the precision of diagnosis and treatment of colorectal cancer (CRC). Microsatellite Instability (MSI) is a key genomic biomarker in colorectal cancer and represents ~15% of the overall CRC population. Those patients whose tumors show MSI, are considered likely to respond to immune checkpoint inhibitor therapy and recommended for it. Conversely, immune checkpoint inhibitor is not routinely recommended for those with tumors that are microsatellite stable (MSS). Prescreening tools that can remove the need to test all patients offer the opportunity to streamline the process and reduce pressure on laboratory staff and resources. Owkin's study published in Nature Communications reveals that MSIntuit CRC can accurately rule out nearly 50% of MSS patients, while correctly classifying more than 96% of MSI patients, on par with current gold standard methods (92-95%). Such new solutions pave the way for an optimized screening workflow to screen more patients, faster.

CLINICAL STUDY

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Nov 08,2023

Groundbreaking Study Indicates Virtual Reality Can Enhance Relationships Between Caregivers and Aging Population

Virtual Reality (VR) is paving the way for enhancing relationships between the aging population and their caregivers, as research from the Virtual Human Interaction Lab (VHIL) at Stanford University demonstrates. The study sought to understand older adults' attitudes towards new technologies, including virtual reality, and how professional caregivers felt about facilitating VR experiences for older adults. Research was led by Dr.Jeremy Bailenson, founding director of the VHIL and one of the world's leading experts on understanding and exploring individual behavior and social responses in VR, and Ryan Christopher Moore, Ph.D. researcher. Key findings include that 81.5% of caregivers reported?they enjoyed interacting with residents more while using Mynd Immersive (Mynd), formerly MyndVR than while doing other activities, and 94.9% said that using Mynd was moderately to extremely beneficial to their relationship with the resident.

CLINICAL STUDY

#virtual reality

#connected device

View Analyst & Ambassador Comments
Go to original news
Nov 07,2023 TOP STORY

AppliedVR Releases Outcomes Data From the Largest Clinical Trial to Study Home-based Virtual Reality Treatment of Chronic Low Back Pain

AppliedVR announced results from a large randomized controlled trial, evaluating virtual reality therapy for treating chronic low back pain at home. The study, which was published in Mayo Clinic Proceedings: Digital Health, found that AppliedVR's RelieVRx program produced clinically meaningful improvements in clinically severe and diverse adults with CLBP. Researchers concluded that the RelieVRx program was superior to a strong, active VR sham at Day 56 (completion of RelieVRx program) for reducing pain intensity and pain interference in a large real-world sample. Specifically, researchers found that study participants who completed the RelieVRx program achieved a reduction in pain intensity by an average of 2.0 points on a pain numerical rating scale, which asks people to rate their pain on a scale of zero to 10. The clinical study was the largest of its kind with a demographically diverse sample, including data from more than 1,000 participants (n=1,067) where approximately half were treated by the RelieVRx program over an eight-week period.

CLINICAL STUDY

#virtual reality

#connected device

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY